TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; and H.R. 1548, Pathway for Biosimilars Act; legislation and proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc., has an indirect interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBRA BARRETT | — |
| ROBERT FALB | — |
| DAVID SANDERS | — |
| TERRI STEWART New | — |
Trade (domestic/foreign) TRD
Trade agreements and other trade matters relating to intellectual property and pharmaceuticals.
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc., has an interest in the issue(s) listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBRA BARRETT | — |
| DAVID SANDERS | — |
Copyright/Patent/Trademark CPT
H.R. 1260, S. 515 & S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; and S. 369, Preserve Access to Affordable Generics Act.
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, Inc., has an interest in the issues listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBRA BARRETT | — |
| DAVID SANDERS | — |
| TERRI STEWART | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.